Related Experiment Video

Updated: Jul 13, 2026

Mapping Hepatic Stellate Cell Morphology in Mouse Models of Liver Fibrosis
06:55

Mapping Hepatic Stellate Cell Morphology in Mouse Models of Liver Fibrosis

Published on: February 13, 2026

Pathologically different features and fibrosis scores in chronic hepatitis C genotypes 3 and 1

Ananya Manuyakorn1, Tawesak Tanwandee, Kanit Atisook

  • 1Department of Pathology, Faculty of Medicine Siriraj Hospital, 2 Pran-nok Rd, Bangkok-noi, Bangkok 10700, Thailand. siama@mahidol.ac.th

Journal of the Medical Association of Thailand = Chotmaihet Thangphaet
|July 13, 2007
PubMed

Insights

Steatosis is more prevalent in chronic hepatitis C genotype 3 compared to genotype 1 in Thailand. Other pathological features and fibrosis scores showed no significant differences between these common hepatitis C genotypes.

Area of Science:

  • Hepatology
  • Virology
  • Pathology

Background:

  • Chronic hepatitis C genotypes 3 and 1 are the most prevalent in Thailand.
  • Understanding genotype-specific pathology is crucial for effective treatment strategies.

Purpose of the Study:

  • To delineate distinct pathological features between hepatitis C virus (HCV) genotypes 3 and 1.
  • To compare fibrosis staging using Knodell Histological Activity Index (HAI) and Ishak modified HAI.

Main Methods:

  • Analysis of pathological features from 114 liver biopsy samples.
  • Histological evaluation for steatosis, inflammation, and fibrosis.
  • Comparison of fibrosis scores between Knodell HAI and Ishak HAI.

Main Results:

  • Steatosis occurred significantly more often in genotype 3 (97.1%) than genotype 1 (77.8%).
  • Portal lymphoid follicles were common; bile duct damage was infrequent.
  • Most patients exhibited Knodell fibrosis stage 1 and Ishak fibrosis stage 3.

Conclusions:

  • Steatosis is a key distinguishing feature of HCV genotype 3.
  • No significant pathological differences were noted beyond steatosis.
  • Knodell fibrosis 1 and Ishak fibrosis 3 represent comparable fibrosis levels.
Abstract

More Related Videos

The Dimethylnitrosamine Induced Liver Fibrosis Model in the Rat09:27

The Dimethylnitrosamine Induced Liver Fibrosis Model in the Rat

Published on: June 17, 2016

3D Imaging of the Liver Extracellular Matrix in a Mouse Model of Non-Alcoholic Steatohepatitis06:46

3D Imaging of the Liver Extracellular Matrix in a Mouse Model of Non-Alcoholic Steatohepatitis

Published on: February 25, 2022

Related Concept Videos

Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...